Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 12, 2009, Pages 5181-5184

  MacGowan, Alasdair P ^a   Reynolds, Rosy ^a   Noel, Alan R ^a   Bowker, Karen E ^a  

^a NORTH BRISTOL NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIOSTASIS; CONTROLLED STUDY; DRUG DISTRIBUTION; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, THEORETICAL; QUINOLINES; STAPHYLOCOCCUS AUREUS;

EID: 71249146344     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00118-09     Document Type: Article

References (14)

1. Ambrose, P. G., S. H. Bhavnani, C. M. Rubino, et al. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
2. Ambrose, P. G., D. M. Grasela, T. H. Grasela, et al. 2001. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45:2793-2797.
3. Booker, B. M., P. F. Smith, A. Forrest, et al. 2005. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype Typhi. Antimicrob. Agents Chemother. 49:1775-1781.
4. Broughall, J. M. 1978. Aminoglycosides, p. 194-206. In D. S. Reeves, I. Phillips, J. D. Williams, and R. Wise (ed.), Laboratory methods in antimicrobial chemotherapy. Churchill Livingstone, Edinburgh, United Kingdom.
5. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing. CLSI M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Drusano, G. L., S. L. Preston, C. Hardalo, et al. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
7. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. 2006. EUCAST Technical Note on daptomycin. Clin. Microbiol. Infect. 12:599-601.
8. European Committee on Antimicrobial Susceptibility Testing. 2007. Ciprofloxacin rationale for the EUCAST clinical breakpoints, version 1.9. www.srga.org/eucastwt/MICTAB/MICquinolones.htm.
9. MacGowan, A. P., K. E. Bowker, and A. R. Noel. 2008. Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 52:1401-1406.
10. MacGowan, A. P., C. A. Rogers, H. A. Holt, et al. 2003. Activities of moxifloxacin against and emergence of resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 47:1088-1095.
11. MacGowan, A. P., et al. 2008. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother./46th Ann. Meet. Infect. Dis. Soc. Am., Washington, DC, 25 to 28 October 2008, abstr. A-993.
12. Noel, A. R., K. E. Bowker, and A. P. MacGowan. 2005. Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 49:4234-4239.
13. Stass, H., A. Dalhoff, D. Kubitza, et al. 1998. Pharmacokinetics, safety and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob. Agents Chemother. 42:2060-2065.
14. Stass, H., and A. Proeve. 1999. Pharmacokinetic/pharmacodynamic estimates for the treatment of community-acquired respiratory tract infections with moxifloxacin, abstr. P772. Ninth Eur. Congr. Clin. Microb. Infect. Dis., Berlin, Germany.